DEX Doesn't Reduce Mortality in Those With Sepsis on Ventilator

Share this content:
DEX Doesn't Reduce Mortality in Those With Sepsis on Ventilator
DEX Doesn't Reduce Mortality in Those With Sepsis on Ventilator

THURSDAY, March 23, 2017 (HealthDay News) -- For patients with sepsis requiring mechanical ventilation, dexmedetomidine is not associated with a reduction in mortality or ventilator-free days, according to a study published online March 21 in the Journal of the American Medical Association. The research was published to coincide with the annual International Symposium on Intensive Care and Emergency Medicine, held from March 21 to 24 in Brussels.

Yu Kawazoe, M.D., Ph.D., from the Tohoku University Graduate School of Medicine in Sendai, Japan, and colleagues randomized patients to receive sedation with or without dexmedetomidine (100 and 101 patients, respectively).

The researchers observed no significant difference in mortality at 28 days in the dexmedetomidine versus the control group (22.8 versus 30.8 percent; hazard ratio, 0.69; 95 percent confidence interval, 0.38 to 1.22; P = 0.20). There was no significant between-group difference in ventilator-free days over 28 days (median, 20 versus 18; P = 0.20). The rate of well-controlled sedation during mechanical ventilation was significantly higher for the dexmedetomidine group (range, 17 to 58 percent versus 20 to 39 percent; P = 0.01); there were no significant between-group differences in other outcomes. Adverse outcomes occurred in 8 and 3 percent of patients in the dexmedetomidine and control groups, respectively.

"Among patients requiring mechanical ventilation, the use of dexmedetomidine compared with no dexmedetomidine did not result in statistically significant improvement in mortality or ventilator-free days," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Higher Fish Intake Appears to Reduce RA Symptoms

Higher Fish Intake Appears to Reduce RA Symptoms

Researchers suggest most varieties of fish may play a role in controlling symptoms

Longer Survival for Midostaurin  Chemotherapy in AML With FLT3

Longer Survival for Midostaurin + Chemotherapy in AML ...

Prolonged overall, event-free survival for patients with acute myeloid leukemia, FLT3 mutation

HIV Testing Inadequate in Young Men Who Have Sex With Men

HIV Testing Inadequate in Young Men Who Have ...

Only 28 percent of young MSM have HIV testing, though they account for 83 percent of new diagnoses

is free, fast, and customized just for you!

Already a member?

Sign In Now »